Skip to main content
SpringerLink
Log in

Resistance to inhibitors of DNA topoisomerases

  • Chapter
Molecular and Clinical Advances in Anticancer Drug Resistance

Part of the book series: Cancer Treatment and Research ((CTAR,volume 57))

Abstract

DNA topoisomerase II (EC 5.99.1.3) is a ubiquitous Mg2+- and ATP-dependent enzyme that exists as a homodimer in eukaryotes (subunit molecular mass 131-180 kDa) and is encoded on human chromosome #17. This enzyme changes the linking number of DNA in steps of two and allows the interconversion of topological isomers of DNA by introducing a transient enzyme-bridged double-strand DNA break. Further details regarding the interaction of type II topoisomerases with DNA can be found in several recent reviews [1–6]. This enzyme has been purified to homogeneity from human Hela cells [7], Saccharomyces cerevisiae [8], Drosophila melanogaster [9], calf thymus [10–12], Trypanosoma cruzi [13], mouse leukemia P388 cells [14], Crithidia fasciculata [15], and Chinese hamster ovary cells [16]; and the gene has been cloned and sequenced from Saccharomyces cerevisiae [17], Schizosaccharomyces pombe [18], Drosophila melanogaster [19], HeLa cells [20], and human Burkitt lymphoma cells [21].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Liu, L.F. DNA topoisomerase-enzymes that catalyse the breaking and rejoining of DNA. CRC Crit. Rev. Biochem. 15:1–24, 1983.

    Article  PubMed  CAS  Google Scholar 

  2. Wang, J.C. DNA topoisomerases. Annu. Rev. Biochem. 54:665–697, 1985.

    Article  PubMed  CAS  Google Scholar 

  3. Vosberg, H.-P. DNA topoisomerases: enzymes that control DNA conformation. Curr. Topics Microbiol. Immunol. 114:19–102, 1985.

    Article  CAS  Google Scholar 

  4. Maxwell, A. and Geliert, M. Mechanistic aspects of DNA topoisomerases. Adv. Prot. Chem. 38:69–107, 1986.

    Article  CAS  Google Scholar 

  5. Wang, J.C. Recent studies of DNA topoisomerases. Biochim. Biophys. Acta. 909:1–9, 1987.

    Article  PubMed  CAS  Google Scholar 

  6. Osheroff, N. Biochemical basis for the interactions of type I and type II topoisomerases with DNA. Pharmacol. Ther. 41:223–241, 1989.

    Article  PubMed  CAS  Google Scholar 

  7. Miller, K.G., Liu, L.F., and Englund, P.T. A homogeneous type II DNA topoisomerase from HeLa cell nuclei. J. Biol. Chem. 256:9334–9339, 1981.

    PubMed  CAS  Google Scholar 

  8. Goto, J. and Wang, J.C. Yeast DNA topoisomerase II. An ATP-dependent type II topoisomerase that catalyzes the catenation, decatenation, unknowing, and relaxation of double-strand DNA rings. J. Biol. Chem. 257:5866–5872, 1982.

    PubMed  CAS  Google Scholar 

  9. Shelton, E.R. Osheroff, N., and Brutlag, D.L. DNA topoisomerase II from Drosophila melanogaster. Purification and physical characterization. J. Biol. Chem. 258:9530–9535, 1983.

    PubMed  CAS  Google Scholar 

  10. Halligan, B.D., Edwards, K.A., and Liu, L.F. Purification and characterization of a type II DNA topoisomerase from bovine calf thymus. J. Biol. Chem. 260:2475–2482, 1985.

    PubMed  CAS  Google Scholar 

  11. Schomburg, W. and Grosse, F. Purification and characterization of DNA topoisomerase II from calf thymus associated with polypeptides of 175 and 150 kDa. Eur. J. Biochem. 160:451–457, 1986.

    Article  PubMed  CAS  Google Scholar 

  12. Strausfeld, U. and Richter, A. Simultaneous purification of DNA topoisomerase I and II from eukaryotic cells. Prep. Biochem. 19:37–48, 1989.

    Article  PubMed  CAS  Google Scholar 

  13. Douc-Rasy, S., Kayser, A., Riou, J., and Riou, G. ATP-independent type II topoisomerase from typanosomes. Proc. Natl. Acad. Sei. USA. 83:7152–7156, 1986.

    Article  CAS  Google Scholar 

  14. Drake, F.H., Zimmerman, J.P., McCabe, F.L., Bartus, H.F., Per, S.R., Sullivan, D.M., Ross, W.E., Mattern, M.R., Johnson, R.K., Crooke, S.T., and Mirabelli, C.K. Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J. Biol. Chem. 262:16739–16747, 1987.

    CAS  Google Scholar 

  15. Melendy, T. and Ray, D.S. Novobiocin affinity purification of a mitochondrial type II topoisomerase from the trypanosomatid Crithidia fasciculata. J.Biol. Chem. 264: 1870–1876, 1989.

    PubMed  CAS  Google Scholar 

  16. Sullivan, D.M., Rowe, T.C., Latham, M.D., and Ross, W.E. Purification and characterization of an altered topoisomerase II from a drug-resistant Chinese hamster ovary cell line. Biochemistry, 28:5680–5687, 1989.

    Article  PubMed  CAS  Google Scholar 

  17. Giaever, G., Lynn, R., Goto, T., and Wang, J.C. The complete nucleotide sequence of the structural gene TOP2 of yeast DNA topoisomerase II. J. Biol. Chem. 261: 12448–12454, 1986.

    PubMed  CAS  Google Scholar 

  18. Uemura, T., Morikawa, K., and Yanagida, M. The nucleotide sequence of the fission yeast DNA topoisomerase II gene: structural and functional relationships to other DNA topoisomerases. EMBO J. 5:2355–2361, 1986.

    PubMed  CAS  Google Scholar 

  19. Wyckoff, E., Natalie, D., Nolan, J.M., Lee, M., and Hsieh, T. Structure of the Drosophila DNA topoisomerase II gene. Nucleotide sequence and homology among topoisomerases II. J. Mol. Biol. 205:1–13, 1989.

    Article  PubMed  CAS  Google Scholar 

  20. Tsai-Pflugfelder, M., Liu, L.F., Liu, A.A., Tewey, K.M., Whang-Peng, J., Knutsen, T., Huebner, K., Croce, CM., and Wang, J.C. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22._Proc. Natl. Acad. Sci. USA 85:7177–7181, 1988.

    Article  CAS  Google Scholar 

  21. Chung, T.D., Drake, F.H., Tan, K.B., R., P.S., Crooke, S.T., and Mirabelli, C.K. Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc. Natl. Acad. Sci. USA 86:9431–9435, 1989.

    Article  PubMed  CAS  Google Scholar 

  22. Liu, L.F., Rowe, T.C., Yang, L., Tewey, K.M., and Chen, G.L. Cleavage of DNA by mammalian DNA topoisomerase II. J. Biol. Chem. 258:15365–15370, 1983.

    PubMed  CAS  Google Scholar 

  23. Osheroff, N. Eukaryotic topoisomerase II. Characterization of enzyme turnover. J. Biol. Chem. 261:9944–9950, 1986.

    PubMed  CAS  Google Scholar 

  24. Osheroff, N. Role of the divalent cation in topoisomerase II mediated reactions. Biochemistry 26:6402–6406, 1987.

    Article  PubMed  CAS  Google Scholar 

  25. Zechiedrich, E.L., Christiansen, K., Andersen, A.H., Westergaard, O., and Osheroff, N. Double-stranded DNA cleavage/religation reaction of eukaryotic topoisomerase II: evidence for a nicked DNA intermediate. Biochemistry 28:6229–6236, 1989.

    Article  PubMed  CAS  Google Scholar 

  26. Andersen, A.H., Christiansen, K., Zechiedrich, E.L., Jensen, P.S., Osheroff, N., and Westergaard, O. Strand specificity of the topoisomerase II mediated double-stranded DNA cleavage reaction. Biochemistry 28:6237–6244, 1989.

    Article  PubMed  CAS  Google Scholar 

  27. Sundin, O. and Varshavsky, A. Arrest of segregation leads to accumulation of highly intertwined catenated dimers: dissection of the final stages of SV40 DNA replication. Cell 25:659–669, 1981.

    Article  PubMed  CAS  Google Scholar 

  28. Nelson, W.G., Liu, L.F., and Coffey, D.S. Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cells. Nature 322: 187–189, 1986.

    Article  PubMed  CAS  Google Scholar 

  29. Brill, S.J., DiNardo, S.K., V.-M., and Sternglanz, R. Need for DNA topoisomerase activity as a swivel for DNA replication for transcription of ribosomal RNA. Nature 326:414–416, 1987.

    Article  PubMed  CAS  Google Scholar 

  30. DiNardo, S., Voelkel, K., and Sternglanz, R. DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication. Proc. Natl. Acad. Sci. USA 81: 2616–2620, 1984.

    Article  PubMed  CAS  Google Scholar 

  31. Holm, C, Goto, T., Wang, J.C., and Botstein, D. DNA topoisomerase II is required at the time of mitosis in yeast. Cell. 41:553–563, 1985.

    Article  PubMed  CAS  Google Scholar 

  32. Uemura, T., Ohkura, H., Adachi, Y., Morino K., Shiozaki, K., and Yanagida, M. DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S.pombe. Cell 50:917–925, 1987.

    Article  PubMed  CAS  Google Scholar 

  33. Rose, D., Thomas, W., and Holm, C. Segregation of recombined chromosomes in meiosis I requires DNA topoisomerase II. Cell 60:1009–1017, 1990.

    Article  PubMed  CAS  Google Scholar 

  34. Berrios, M., Osheroff, N., and Fisher, P.A. In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophila nuclear matrix fraction. Proc. Natl. Acad. Sci. USA 82:4142–4146, 1985.

    Article  PubMed  CAS  Google Scholar 

  35. Earnshaw, W.C., Halligan, B., Cooke, CA., Heck, M.M., and Liu, L.F. Topoisomerase II is a structural component of mitotic chromosome scaffolds. J. Cell Biol. 100:1706–1715, 1985.

    Article  PubMed  CAS  Google Scholar 

  36. Schroder, H.C., Trolltsch, D., Friese, U., Bachmann, M., and Muller, W.E. Mature mRNA is selectively released from the nuclear matrix by an ATP/dATP-dependent mechanism sensitive to topoisomerase inhibitors. J. Biol. Chem. 262:8917–8925, 1987.

    PubMed  CAS  Google Scholar 

  37. Tsutsui, K., Tsutsui, K., and Muller, M.T. The nuclear scaffold exhibits DNA-binding sites selective for supercoiled DNA. J. Biol. Chem. 263:7235–7241, 1988.

    PubMed  CAS  Google Scholar 

  38. Adachi, Y., Kas, E., and Laemmli, U.K. Preferential, cooperative binding of DNA topoisomerase II to scaffold-associated regions. EMBO J. 8:3997–4006, 1989.

    PubMed  CAS  Google Scholar 

  39. To, R.Q. and Kmiec, E.R. Assembly of transcriptionally active chromatin in vitro: a possible role for topoisomerase II. Cell Growth Different. 1:39–45, 1990.

    CAS  Google Scholar 

  40. Ross, W.E., Glaubiger, D.L., and Kohn, K.W. Protein-associated DNA breaks in cells treated with adriamycin or ellipticine. Biochim. Biophys. Acta 519:23–30, 1978.

    Article  PubMed  CAS  Google Scholar 

  41. Ross, W.E., Glaubiger, D., and Kohn, K.W. Qualitative and quantitative aspects of intercalator-induced DNA strand breaks. Biochim. Biophys. Acta 562:41–50, 1979.

    Article  PubMed  CAS  Google Scholar 

  42. Ross, W.E. and Bradley, M.O. DNA double-strand breaks in mammalian cells after exposure to intercalating agents. Biochim. Biophys. Acta 654:129–134, 1981.

    Article  PubMed  CAS  Google Scholar 

  43. Zwelling, L.A., Michaels, S., Erickson, L.C., Ungerleider, R.S., Nichols, M., and Kohn, K.W. Protein-associated deoxyribonucleis acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4′-(9-acridinylamino) methanesulfon-m-anisidide and adriamycin. Biochemistry 20:6553–6563, 1981.

    Article  PubMed  CAS  Google Scholar 

  44. Wozniak, A. J. and Ross, W.E. DNA damage as a basis for 4′-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity. Cancer Res. 43:120–124, 1983.

    PubMed  CAS  Google Scholar 

  45. Ross, W., Rowe, T., Glisson, B., Yalowich, J., and Liu, L. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res. 44:5857–5860, 1984.

    PubMed  CAS  Google Scholar 

  46. Pommier, Y., Mattern, M.R., Schwartz, R.E., Zwelling, L.A., and Kohn, K.W. Changes in deoxyribonucleic acid linking number due to treatment of mammalian cells with the intercalating agent 4′-(9-acridinylamino) methanesulfon-m-anisidide. Biochemistry 23: 2927-2932, 1984.

    Google Scholar 

  47. Tewey, K.M., Chen, G.L., Nelson, E.M., and Liu, L.F. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem. 259:9182–9187, 1984.

    PubMed  CAS  Google Scholar 

  48. Chen, G.L., Yang, L., Rowe, T.C., Halligan, B.D., Tewey, K.M., and Liu, L.F. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem. 259:13560–13566, 1984.

    PubMed  CAS  Google Scholar 

  49. Tewey, K.M., Rowe, T.C., Yang, L., Halligan, B.D., and Liu, L.F. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226:466–468, 1984.

    Article  PubMed  CAS  Google Scholar 

  50. Nelson, E.M., Tewey, K.M., and Liu, L.F. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acridinylamino) methanesulfon-m-anisidide. Proc. Natl. Acad. Sci. USA 81:1361–1365, 1984.

    Article  PubMed  CAS  Google Scholar 

  51. Pommier, Y., Minford, J.K., Schwartz, R.E., Zwelling, L.A., and Kohn, K.W. Effects of the DNA intercalators 4′-(9-acridinylamino) methanesulfon-m-anisidide and 2-methyl-9-hydroxyellipticinium on topoisomerase II mediated DNA strand cleavage and strand passage. Biochemistry 24:6410–6416, 1985.

    Article  PubMed  CAS  Google Scholar 

  52. Osheroff, N. Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide. Biochemistry 28:6157–6160, 1989.

    Article  PubMed  CAS  Google Scholar 

  53. Holm, C, Covey, J.M., Kerrigan, D., and Pommier, Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res. 49:6365–6368, 1989.

    PubMed  CAS  Google Scholar 

  54. Robinson, M.J. and Osheroff, N Stabilization of the topoisomerase II-DNA cleavage complex by antineoplastic drugs: inhibition of enzyme-mediated DNA religation by 4′-(9-acridinylamino) methanesulfon-m-anisidide. Biochemistry 29:2511–2515, 1990.

    Article  PubMed  CAS  Google Scholar 

  55. Batist, G., Tulpule, A., Sinha, B.K., Katki, A.G., Myers, C.E., and Cowan, K.H. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J. Biol. Chem. 261:15544–15549, 1986.

    PubMed  CAS  Google Scholar 

  56. Sinha, B.K., Haim, N., Dusre, L., Kerrigan, D., and Pommier, Y. DNA strand breaks produced by etoposide (VP-16, 213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action. Cancer Res. 48:5096–5100, 1988.

    PubMed  CAS  Google Scholar 

  57. Politi, P.M. and Sinha, B.K. Role of differential drug, efflux, and binding of etoposide in sensitive and resistant human tumor cell lines: implications for the mechanisms of drug resistance. Mol. Pharmacol. 35:271–278, 1989.

    PubMed  CAS  Google Scholar 

  58. Mimnaugh, E.G., Dusre, L., Atwell, J., and Myers, C. Differential oxygen radical susceptibility of adriamycin-sensitive and-resistant MCF-7 human breast tumor cells. Cancer Res. 49:8–15, 1989.

    PubMed  CAS  Google Scholar 

  59. Gupta, R.S. Genetic, biochemical, and cross-resistance studies with mutants of Chinese hamster ovary cells resistant to the anticancer drugs, VM-26 and VP16-213._Cancer Res. 43:1568–1574, 1983.

    PubMed  CAS  Google Scholar 

  60. Glisson, B., Gupta, R., Hodges, P., and Ross, W. Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence for a common intracellular target. Cancer Res. 46:1939–1942, 1986.

    PubMed  CAS  Google Scholar 

  61. Glisson, B.R., Gupta, S.S., S.-K., and Ross, W. Characterization of acquired epipodo-phyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity. Cancer Res. 46:1934–1938, 1986.

    PubMed  CAS  Google Scholar 

  62. Beran, M. and Andersson, B.S. Development and characterization of a human myclogenous leukemia cell line resistant to 4′-(9′ acridinylamino)-3-methanesulfon-m-anisidide. Cancer Res. 47:1897–1904, 1987.

    PubMed  CAS  Google Scholar 

  63. Bakic, M., Beran, M., Andersson, B.S., Silberman, L., Estey, E., and Zwelling, L.A. The production of topoisomerase II-mediated DNA cleavage in human leukemia cells predicts their susceptibility to 4′-(9-acridinylamino) methanesulfon-m-anisidide (m-AMSA).Biochem. Biophys. Res. Commum. 134:638–645, 1986.

    Article  CAS  Google Scholar 

  64. Bakic, M., Chan, D., Andersson, B.S., Beran, M., Silberman, L., Jïstey, E., Ricketts, L., and Zwelling, L.A. Effect of 1-B-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4′-(9-acridinylamino)-methanesulfon-m-aniside (m-AMSA) and etoposide in m-AMSA-sensitive and-resistant human leukemia cells. Biochem. Pharmacol. 36:4067–4078, 1987.

    Article  PubMed  CAS  Google Scholar 

  65. Estey, E.H., Silberman, L., Beran, M., Andersson, B.S., and Zwelling, L.A. The interaction between nuclear topoisomerase II activity from human leukemia cells, exogenous DNA, and 4′-(9-acridinylamino) methanesulfon-m-anisidide (m-AMSA) or 4-(4,6-O-ethylidene-B-D-glucopyranoside) (VP-16) indicates the sensitivity of the cells to the drugs. Biochem. Biophys. Res. Commun. 144:787–793, 1987.

    Article  PubMed  CAS  Google Scholar 

  66. Zwelling, L.A., Hinds, M., Chan, D., Mayes, J., Sie, K.L., Parker, E., Silberman, L., Radcliffe, A., Beran, M., and Blick, M. Characterization of an amsacrine-resistant line of human leukemia cells. J. Biol. Chem. 264:16411–16420, 1989.

    PubMed  CAS  Google Scholar 

  67. Yoshida, H.T., Kojima, T., Yamagishi, J, and Nakamura, S. Quinolone-resistant mutations of the gyrA gene of Escherichia coli. Mol. Gen. Genet. 211:1–7, 1988.

    Article  CAS  Google Scholar 

  68. Danks, M.K., Yalowich, J.C., and Beck, W.T. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26).Cancer Res. 47:1297–1301, 1987.

    PubMed  CAS  Google Scholar 

  69. Danks, M.K., Schmidt, CA., Cirtain M.C., Suttle, D.P., and Beck, W.T. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected from resistance to VM-26._Biochemistry 27:8861–8869, 1988.

    Article  PubMed  CAS  Google Scholar 

  70. Beck, W.T., Cirtain, M.C., Danks, M.K., Felsted Safa, A.R., Wolverton, J.S., Suttle, D.P., and Trent, J.M. Pharmacological, molecular, and cytogenetic analysis of “ atypical” multidrug-resistant human leukemic cells. Cancer Res. 47:5455–5460, 1987.

    PubMed  CAS  Google Scholar 

  71. Wolverton, J.S., Danks, M.K., Schmidt, CA., and Beck, W.T. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells. Cancer Res. 49:2422–2426, 1989.

    PubMed  CAS  Google Scholar 

  72. Danks, M.K., Schmidt, CA., Deneka, D.A., and Beck, W.T. Altered interaction of ATP with DNA topoisomerase II from VM-26-resistant CEM cells. Proc. Am. Assoc. Cancer Res. 30:524, 1989.

    Google Scholar 

  73. Danks, M.K., Schmidt, CA., Deneka, D.A., and Beck, W.T. Increased ATP requirement for activity of and complex formation by DNA topoisomerase II from human leukemic CCRF-CEM cells selected for resistance to teniposide. Cancer Commun. 1: 101–109, 1989.

    PubMed  CAS  Google Scholar 

  74. Fernandes, DJ., Danks, M.K., and Beck, W.T. Decreased nuclear matrix DNA topoisomerase II (topo II) in VM-26 resistant human leukemia cells. Proc. Am. Assoc. Cancer Res. 30:502, 1989.

    Google Scholar 

  75. Per, S.R., Mattern, M.R., Mirabelli, C.K. Drake, F.H., Johnson, R.K., and Crooke, S.T. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function. Mol. Pharmacol. 32:17–25, 1987.

    PubMed  CAS  Google Scholar 

  76. Drake, F.H., Hofmann, G.A., Bartus, H.F., Mattern, M.R., Crooke, S.T., and Mirabelli, C.K. Biochemical and pharmacological properties of pl70 and pl80 forms of topoisomerase II. Biochemistry 28:8154–8160, 1989.

    Article  PubMed  CAS  Google Scholar 

  77. Tan, K.B., Mattern, M.R., Boyce, R.A., and Schein, P.S. Elevated DNA topoisomerase II activity in nitrogen mustard-resistant human cells. Proc. Natl. Acad. Sci. USA 84: 7668–7671, 1987.

    Article  PubMed  CAS  Google Scholar 

  78. Tan, K.B., Mattern M.R., Boyce, R.A., and Schein, P.S. Unique sensitivity of nitrogen mustard-resistant human Burkitt lymphoma cells to novobiocin. Biochem. Pharmacol. 37:4411–4413, 1988.

    Article  PubMed  CAS  Google Scholar 

  79. Tan, K.B., Per, S.R., Boyce, R.A., Mirabelli, C.K., and Crooke, S.T. Altered expression and transcription of the topoisomerase II gene in nitrogen mustard-resistant human cells. Biochem. Pharmacol. 37:4413–4416, 1988.

    Article  PubMed  CAS  Google Scholar 

  80. Ferguson, P.J., Fisher, M.H., Stephenson, J., Li, D., Zhou, B., and Cheng, Y. Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res. 48:5956–5964, 1988.

    PubMed  CAS  Google Scholar 

  81. Liu, S.Y., Hwang, B.D., Haruna, M., Imakura, Y., Lee, K.H., and Cheng, Y.C. Podophyllotoxin analogs: effects on DNA topoisomerase II, tubulin polymerization, human tumor KB cells, and their VP-16 resistant variants. Mol. Pharmacol. 36:78–82, 1989.

    PubMed  CAS  Google Scholar 

  82. Johnson, R.K., Ovejera, A.A., and Goldin, A. Activity of anthracyclines against an adriamycin (NSC-123127)-resistant subline of P388 leukemia with special emphasis on cinerubin A (NSC-18334).Cancer Treat. Rep. 60:99–102, 1976.

    PubMed  CAS  Google Scholar 

  83. Goldenberg, G.J., Wang, H., and Blair, G.W. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single-and double-strand breakage in cloned cell lines of adriamycin-sensitive and-resistant P388 leukemia. Cancer Res. 46:2978–2983, 1986.

    PubMed  CAS  Google Scholar 

  84. Deffie, A.M., Alam, T., Seneviratne, C, Beenken, S.W., Batra, J.K., Shea, T.C., Henner, W.D., and Goldenberg, G.J. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and resistant P388 leukemia. Cancer Res. 48:3595–3602, 1988.

    PubMed  CAS  Google Scholar 

  85. Seneviratne, C. and Goldenberg, G.J. Further characterization of drug-sensitivity and cross-resistance profiles of cloned cell lines of adriamycin-sensitive and-resistant P388 leukemia. Cancer Commun. 1:21–27, 1989.

    PubMed  CAS  Google Scholar 

  86. Deffie, A.M., Batra, J.K., and Goldenberg, G.J. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and-resistant P388 leukemia cell lines. Cancer Res. 49:58–62, 1989.

    PubMed  CAS  Google Scholar 

  87. Deffie, A.M., Bosman, D.J., and Goldenberg, G.J. Evidence for a mutant allele of the gene for DNA topoisomerase II in adriamycin-resistant P388 murine leukemia cells. Cancer Res. 49:6879–6882, 1989.

    PubMed  CAS  Google Scholar 

  88. Tan, K.B., Mattern, M.R., Eng, W., McCabe, F.L., and Johnson, R.K. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J. Natl. Cancer Inst. 81:1732–1735, 1989.

    Article  PubMed  CAS  Google Scholar 

  89. Salles, B., Charcosset, J.Y., and Jacquemin-Sablon, A. Isolation and properties of Chinese hamster lung cells resistant to ellipticine derivatives. Cancer Treat. Rep. 66: 327–338, 1982.

    PubMed  CAS  Google Scholar 

  90. Charcosset, J.Y., Bendirdjian, J.P., Lantieri M.F., and Jacquemin-Sablon, A. Effects of 9-OH-ellipticine on cell survival, macromolecular syntheses, and cell cycle progression in sensitive and resistant Chinese hamster lung cells. Cancer Res. 45:4229–4236, 1985.

    PubMed  CAS  Google Scholar 

  91. Pommier, Y., Schwartz, R.E., Zwelling, L.A., Kerrigan, D., Mattern, M.R., Charcosset, J.Y., Jacquemin-Sablon, A., and Kohn, K.W. Reduced formation of protein-associated DNA strand breaks in Chinese hamster cells resistance to topoisomerase II inhibitors. Cancer Res. 46:611–616, 1986.

    PubMed  CAS  Google Scholar 

  92. Pommier, Y., Kerrigan, D., Schwartz, R.E., Swack, J.A., and McCurdy, A. Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res. 46:3075–3081, 1986.

    PubMed  CAS  Google Scholar 

  93. Pommier, Y., Kerrigan, D., and Kohn, K.W. Topoisomerase alterations associated with drug resistance in a line of Chinese hamster cells. NCI Monogr. 4:83–7, 1987.

    PubMed  Google Scholar 

  94. Pommier, Y., Kerrigan, D., Covey, J.M., Kao-Shan, C.S., and Whang-Peng, J. Sister chromatid exchanges, chromosomal aberrations and cytotoxicity produced by antitumor topoisomerase II inhibitors in sensitive (DC3F) and resistant (DC3F/9-OHE) Chinese hamster cells. Cancer Res. 48:512–516, 1988.

    PubMed  CAS  Google Scholar 

  95. Charcosset, J.Y., Saucier, J.M., and Jacquemin-Sablon, A. Reduced DNA topoisomerase II activity and drug-stimulated DNA cleavage in 9-hydroxyellipticine resistant cells. Biochem. Pharmacol. 37:2145–2149, 1988.

    Article  PubMed  CAS  Google Scholar 

  96. Delaporte, C, Charcosset, J.Y., and Jacquemin-Sablon, A. Effects of verapamil on the cellular accumulations and toxicity of several antitumor drugs in 9-hydroxy-ellipticine-resistant cells. Biochem. Pharmacol. 37:613–619, 1988.

    Article  PubMed  CAS  Google Scholar 

  97. Markovits, J., Linassier, C., Fosse, P., Couprie, J., Pierre, J., Jacquemin-Sablon, A., Saucier, J.M., Le Pecq, J.B., and Larsen, A.K. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res. 49:5111–5117, 1989.

    PubMed  CAS  Google Scholar 

  98. Robson, C.N., Hoban, P.R., Harris, A.L., and Hickson, I.D. Cross-sensitivity to topoisomerase II inhibitors in cytotoxic drug-hypersensitive Chinese hamster ovary cell lines. Cancer Res. 47:1560–1565, 1987.

    PubMed  CAS  Google Scholar 

  99. Davies, S.M., Robson, C.N., Davies, S.L., and Hickson, I.D. Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J. Biol. Chem. 263:17724–17729, 1988.

    PubMed  CAS  Google Scholar 

  100. Fernandes, DJ., Smith-Nanni, C, Paff, M.T., and Neff, T.A. Effects of antileukemia agents on nuclear matrix-bound DNA replication in CCRF-CEM leukemia cells. Cancer Res. 48:1850–1855, 1988.

    PubMed  CAS  Google Scholar 

  101. Roberts, D., Lee, T., Parganas, E., Wiggins, L., Yalowich, J., and Ashmun, R. Expressions of resistance and cross-resistance in teniposide-resistant L1210 cells. Cancer Chemother. Pharmacol. 19:123–130, 1987.

    Article  PubMed  CAS  Google Scholar 

  102. Roberts, D., Foglesong, D., Parganas, E., and Wiggins, L. Reduced formation of lesions in the DNA of a multidrug-resistant L1210 subline selected for teniposide resistance. Cancer Chemother. Pharmacol, 23:161–168, 1989.

    PubMed  CAS  Google Scholar 

  103. Ganapathi, R., Grabowski, D., Ford, J., Heiss, C, Kerrigan, D., and Pommier, Y. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with tnultidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage. Cancer Commun. 1:217–224, 1989.

    PubMed  CAS  Google Scholar 

  104. Ganapathi, R. and Grabowski, D. Differential effect of the calmodulin inhibitor trifluoperazine in modulating cellular accumulation, retention and cytotoxicity of doxorubicin in progressively doxorubicin-resistant L1210 mouse leukemia cells. Biochem. Pharmacol. 37:185–193, 1988.

    Article  PubMed  CAS  Google Scholar 

  105. Zijlstra, J.G., de Vries, E.G., and Mulder, N.H. Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res. 47:1780–1784, 1987.

    PubMed  CAS  Google Scholar 

  106. Zijlstra, J.G., de Vries, E.G.E., Muskiet, F.A.J., Martini, I.A., Timmer-Bosscha, H., and Mulder, N.H. Influence of docosahexaenoic acid in vitro on intracellular adriamycin concentration in lymphocytes and human adriamycin-sensitive and-resistant small-cell lung cancer cell lines, and on cytotoxicity in the tumor cell lines. Int. J. Cancer. 40: 850-856, 1987.

    Google Scholar 

  107. de Jong, S., Zijlstra, J.G., de Vries, E.G.E., and Mulder, N.H. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res. 50:304–309, 1990.

    PubMed  Google Scholar 

  108. Slovak, M.L., Hoeltge, G.A., Dalton W.S., and Trent, J.M. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Res. 48:2793–2797, 1988.

    PubMed  CAS  Google Scholar 

  109. Wallace, R.E., Lindh, D., and Durr, F.E. Studies on the development of resistance to mitoxantrone in human colon carcinoma cells in vitro. Proc. Am. Assoc. Cancer Res. 23:767, 1982.

    Google Scholar 

  110. Dalton, W.S., Cress, A.E., Alberts, D.S., and Trent, J.M. Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. Cancer Res. 48:1882–1888, 1988.

    PubMed  CAS  Google Scholar 

  111. Marsh, W., Sicheri, D., and Center, M.S. Isolation and characterization of adriamycin-resistant HL-60 cells which are not defective in the initial intracellular accumulation of drug. Cancer Res. 46:4053–4057, 1986.

    PubMed  CAS  Google Scholar 

  112. Marsh, W. and Center, M.S. Adriamycin resistance in HL60 cells and accompanying modification of a surface membrane protein contained in drug-sensitive cells. Cancer Res. 47:5080–5086, 1987.

    PubMed  CAS  Google Scholar 

  113. McGrath, T. and Center, M.S. Mechanisms of multidrug resistance in HL60 cells: evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug. Cancer Res. 48:3959–3963, 1988.

    PubMed  CAS  Google Scholar 

  114. Lutzky, J., Astor, M.B., Taub, R.N., Baker, M.A., Bhalla, K., Gervasoni, J., J. E., Rosado, M., Stewart, V., Krishna, S, and Hindenburg, A.A. Role of glutathione and dependent enzymes in anthracycline-resistant HL60/AR cells. Cancer Res. 49:4120–4125, 1989.

    PubMed  CAS  Google Scholar 

  115. Hindenburg, A.A., Gervasoni, J., J.E., Krishna, S., Stewart, V.J., Rosado, M., Lutzky, J., Bhalla, K., Baker, M.A., and Taub, R.N. Intracellular distribution and phar-macokinetics of daunorubicin in anthracycline-sensitive and-resistant HL-60 Cells. Cancer Res. 49:4607–4614, 1989.

    PubMed  CAS  Google Scholar 

  116. Bhalla, K., Hindenburg, A., Taub, R.N., and Grant, S. Isolation and characterization of an anthracycline-resistant human leukemic cell line. Cancer Res. 45:3657–3662, 1985.

    PubMed  CAS  Google Scholar 

  117. Remnick, R.A., Gervasoni, J., J. E., Hindenburg, A.A., Lutzky, Krishna, S., Rosado, M., and Taub, R.N. The subcellular distribution of daunorubicin in drug resistant cell lines that do and do not overexpress the P-glycoprotein. Proc. Am. Assoc. Cancer Res. 30:511, 1989.

    Google Scholar 

  118. Supino, R., Prosperi, E., Formelli, F., Mariani, M, and Parmiani, G. Characterization of a doxorubicin-resistant murine melanoma line: studies on cross-resistance and its circumvention. Br. J. Cancer 54:33–42, 1986.

    Article  PubMed  CAS  Google Scholar 

  119. Supino, R., Mariani, M., Capranico, G., Colombo, A., and Parmiani, G. Doxorubicin cellular pharmacokinetics and DNA breakage in a multi-drug resistant B16 melanoma cell line. Br. J. Cancer 57:142–146, 1988.

    Article  PubMed  CAS  Google Scholar 

  120. McGrath, T., Marquardt, D., and Center, M.S. Multiple mechanisms of adriamycin resistance in the human leukemia cell line CCRF-CEM. Biochem. Pharmacol. 38: 497–501, 1989.

    Article  PubMed  CAS  Google Scholar 

  121. Harker, W.G., Slade, D.L., Dalton W.S., Meltzer, P.S., and Trent, J.M. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Res. 49:4542–4549, 1989.

    PubMed  CAS  Google Scholar 

  122. Ishida, R., Nishizawa, M., Fukami, K., Maekawa, K., Takahashi, T., and Nishimoto, T. Isolation and characterization of novobiocin-resistant BHK cells. Somat. Cell Mol. Genet. 13:11–20, 1987.

    Article  PubMed  CAS  Google Scholar 

  123. Ishida, R., Nishizawa, M., Nishimoto, T., and Takahashi, T. Cross-resistance of novobiocin-resistant BHK cell line to topoisomerase II inhibitors. Somat. Cell Mol. Genet. 14:489–497, 1988.

    Article  PubMed  CAS  Google Scholar 

  124. Jeggo, P.A. and Kemp, L.M. X-ray-sensitive mutants of Chinese hamster ovary cell line. Isolation and cross-sensitivity to other DNA-damaging agents. Mutat. Res. 112:313–327, 1983.

    Article  PubMed  CAS  Google Scholar 

  125. Kemp, L.M., Sedgwick, S.G., and Jeggo, P.A. X-ray sensitive mutants of Chinese hamster ovary cells defective in double-strand break rejoining. Mutat. Res. 132:189–196, 1984.

    Article  PubMed  CAS  Google Scholar 

  126. Weibezahn, K.F., Lohrer, H., and Herrlich, P. Double-strand break repair and G2 block in Chinese hamster ovary cells and their radiosensitive mutants. Mutat. Res. 145:177–183, 1985.

    Article  PubMed  CAS  Google Scholar 

  127. Jeggo, P.A., Caldecott, K., Pidsley, S., and Banks, G.R. Sensitvity of Chinese hamster ovary mutants defective in DNA double strand break repair to topoisomcrase II inhibitors. Cancer Res. 49:7057–7063, 1989.

    PubMed  CAS  Google Scholar 

  128. Evans, H.H., Ricanati, M., Horng, M.F., and Mencl, J. Relationship between topoisomerase II and radiosensitivity in mouse L5178Y lymphoma strains. Mutat. Res. 217:53–63, 1989.

    Article  PubMed  CAS  Google Scholar 

  129. Sander, M., Nolan J.M., and Hsieh, T.S. A protein kinase activity tightly associated with Drosophila type II DNA topoisomerase. Proc. Natl. Acad. Sci. USA 81:6938–6942, 1984.

    Article  PubMed  CAS  Google Scholar 

  130. Ackerman, P., Glover, C.V., and Osheroff, N. Phosphorylation of DNA topoisomerase II by casein kinase II: modulation of eukaryotic topoisomerase II activity in vitro. Proc. Natl. Acad. Sci. USA 82:3164–3168, 1985.

    Article  CAS  Google Scholar 

  131. Sahyoun, N., Wolf, M., Besterman, J., Hsieh, T.S., Sander, M., LeVine, I., H., Chang, K.J., and Cuatrecasas, P. Protein kinase C phosphorylates topoisomerase II: topoisomerase activation and its possible role in phorbol ester-induced differentiation of HL-60 cells. Proc. Natl. Acad. Sci. USA 83:1603–1607, 1986.

    Article  PubMed  CAS  Google Scholar 

  132. Rottmann, M., Schroder, H.C., Gramzow, M., Renneisen, K., Kurelec, B., Dorn, A., Friese, U., and Muller, W.E.G. Specific phosphorylation of proteins in pore complex-laminae from the sponge Geodia cydonium by the homologous aggregation factor and phorbol ester. Role of protein kinase C in the phosphorylation of DNA topoisomerase II. EMBO J. 6:3939–3944, 1987.

    CAS  Google Scholar 

  133. Ackerman, P., Glover, C.V.C., and Osheroff, N. Phosphorylation of DNA topoisomerase II in vivo and in total homogenates of Drosophila Kc cells. J. Biol. Chem. 263: 12653–12660, 1988.

    PubMed  CAS  Google Scholar 

  134. Heck, M.M.S., Hittelman, W.N., and Earnshaw, W.C. In vivo phophorylation of the 170-kDa form of eukaryotic DNA topoisomerase II. J. Biol. Chem. 264:15161–15164, 1989.

    PubMed  CAS  Google Scholar 

  135. Darby, M.K., Schmitt, B., Jongstra-Bilen, J., and Vosberg, H.P. Inhibition of calf thymus type II DNA topoisomerase by poly(ADP-ribosylation).EMBO J. 4:2129–2134, 1985.

    PubMed  CAS  Google Scholar 

  136. Maniar, N., Krishan, A., Israel, M., and Samy, T.S.A. Anthracycline-induced DNA breaks and resealing in doxorubicin-resistant murine leukemic P388 cells. Biochem. Pharmacol. 37:1772, 1988.

    Article  Google Scholar 

  137. Krishan, A., Sauerteig, A., and Wellham, L.L. Flow cytometric studies on modulation of cellular adriamycin retention by phenothiazines. Cancer Res. 45:1046–1051, 1985.

    PubMed  CAS  Google Scholar 

  138. Darkin, S.J. and Ralph, R.K. A protein factor that enhances amsacrine-mediated formation of topoisomerase II-DNA complexes in murine mastocytoma cell nuclei. Biochim. Biophys. Acta. 1007:295–300, 1989.

    Article  CAS  Google Scholar 

  139. Duguet, M., Lavenot, C, Harper, F., Mirambeau, G., and DeRecondo, A.M. DNA topoisomerases from rat liver: physiological variations. Nucleic Acid Res. 11:1059–1075, 1983.

    Article  PubMed  CAS  Google Scholar 

  140. Miskimins, R., Miskimins W.K., Bernstein, H., and Shimizu, N. Epidermal growth factor-induced topoisomerase(s).Exp. Cell Res. 146:53–62, 1983.

    Article  PubMed  CAS  Google Scholar 

  141. Taudou, G., Mirambeau, G., Lavenot, C, A., D. G., Vermeersch, J., and Duguet, M. DNA topoisomerase activities in concanavalin A-stimulated lymphocytes. FEBS. 176: 431–435, 1984.

    Article  CAS  Google Scholar 

  142. Tricoli, J.V., Sahai, B.M., McCormick, P.J., Jarlinski, S.J., Bertram, J.S., and Kowalski, D. DNA topoisomerase I and II activities during cell proliferation and the cell cycle in cultured mouse embryo fibroblast (C3H 10T1/2) cells. Exp. Cell Res. 158:1–14, 1985.

    Article  PubMed  CAS  Google Scholar 

  143. Sullivan, D.M., Glisson, B.S., Hodges, P.K., Smallwood-Kentro, S., and Ross, W.E. Proliferation dependence of topoisomerase II mediated drug action. Biochemistry 25: 2248–2256, 1986.

    Article  PubMed  CAS  Google Scholar 

  144. Sullivan, D.M., Latham, M.D., and Ross, W.E. Proliferation-dependent topoisomerase II content as a determinant of anti-neoplastic drug action in human, mouse, and Chinese hamster ovary cells. Cancer Res. 47:3973–3979, 1987.

    PubMed  CAS  Google Scholar 

  145. Zwelling, L.A., Estey, E., Silberman, L., Doyle, S., and Hittelman, W. Effect of cell proliferation and chromatin conformation on intercalator-induced, protein-associated DNA cleavage in human brain tumor cells and human fibroblasts. Cancer Res. 47: 251–257, 1987.

    PubMed  CAS  Google Scholar 

  146. Robbie, M.A., Baguley, B.C., Denny, W.A., Gavin, J.B., and Wilson, W.R. Mechanism of resistance of noncycling mammalian cells to 4′-(9-acridinylamino) methanesulfon-zn-anisidide: comparison of uptake, metabolism, and DNA breakage in log-and plateau-phase Chinese hamster fibroblast cell cultures. Cancer Res. 48:310–319, 1988.

    PubMed  CAS  Google Scholar 

  147. Schneider, E., Darkin, S.J., Robbie, M.A., Wilson, W.R., and Ralph, R.K. Mechanism of resistance of non-cycling mammalian cells to 4’-[9-acridinylamino] methanesulphon-w-anisidide: role of DNA topoisomerase II in log-and plateau-phase CHO cells. Biochim. Biophys. Acta 949:264–272, 1988.

    Article  PubMed  CAS  Google Scholar 

  148. Hsiang, Y.H., Wu, H.Y., and Liu, L.F. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res. 48:3230–3235, 1988.

    PubMed  CAS  Google Scholar 

  149. Nelson, W.G., Cho, K.R., Hsiang, Y.H., Liu, L.F., and Coffey, D.S. Growth-related elevations of DNA topoisomerase II levels found in Dunning R3327 rat prostatic adenocarcinomas. Cancer Res. 47:3246–3250, 1987.

    PubMed  CAS  Google Scholar 

  150. Heck, M.M. and Earnshaw, W.C. Topoisomerase II: a specific marker for cell proliferation. J. Cell Biol. 103:2569–2581, 1986.

    Article  PubMed  CAS  Google Scholar 

  151. Fairman, R. and Brutlag, D.L. Expression of the Drosophila type II topoisomerase is developmentally regulated. Biochemistry 27:560–565, 1988.

    Article  PubMed  CAS  Google Scholar 

  152. Chow, K.C. and Ross, W.E. Topoisomerase-specific drug sensitivity in relation to cell cycle progression. Mol. Cell. Biol. 7:3119–3123, 1987.

    PubMed  CAS  Google Scholar 

  153. Estey, E., Adlakha, R.C., Hittelman, W.N., and Zwelling, L.A. Cell cycle stage dependent variations in drug-induced topoisomerase II mediated DNA cleavage and cytotoxicity. Biochemistry 26:4338–4344, 1987.

    Article  PubMed  CAS  Google Scholar 

  154. Heck, M.M.S., Hittelman, W.N., and Earnshaw, W.C. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc. Natl. Acad. Sci. USA 85:1086–1090, 1988.

    Article  PubMed  CAS  Google Scholar 

  155. Markovits, J., Pommier, Y., Kerrigan, D., Coery, J.M., Tilchen, E.J., and Kohn, K.W. Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells. Cancer Res. 47: 2050-2055, 1987.

    Google Scholar 

  156. Woessner, R.D., Chung, T.D.Y., Hofmann, G.A., Mattern, M.R., Mirabelli, C.K., Drake, F.H., and Johnson, R.K. Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170kD and 180kD forms of topoisomerase II. Cancer Res. 50:2901–2908, 1990.

    PubMed  CAS  Google Scholar 

  157. Long, B.H., Musial, S.T., and Brattain, M.G. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide. Cancer Res. 46:3809–3816, 1986.

    PubMed  CAS  Google Scholar 

  158. Brox, L.W., Belch, A., Ng, A., and Pollock, E. Loss of viability and induction of DNA damage in human leukemic myeloblasts and lymphocytes by ml-AMSA. Cancer Chemother. Pharmacol. 17:127–132, 1986.

    Article  PubMed  CAS  Google Scholar 

  159. Priel, E., Aboud, M., Feigelman, H., and Segal, S. Topoisomerase II activity in human leukemic and lymphoblastoid cells. Biochem. Biophys. Res. Comm. 130:325–332, 1985.

    Article  PubMed  CAS  Google Scholar 

  160. Edwards, CM., Glisson, B.S., King, C.K., Smallwood-Kentro, S., and Ross, W.E. Etoposide-induced DNA cleavage in human leukemia cells. Cancer Chemother. Pharmacol. 20:162–168, 1987.

    Article  PubMed  CAS  Google Scholar 

  161. Potmesil, M., Hsiang, Y.H., Liu, L.F., Wu, H.Y., Traganos, F., Bank, B., and Silber, R. DNA topoisomerase II as a potential factor in drug resistance of human malignancies. NCI Monogr. 4:105–109, 1987.

    PubMed  Google Scholar 

  162. Potmesil, M., Hsiang, Y.H., Liu, L.F., Bank, B., Grossberg, H., Kirschenbaum, S., Forlenzar, T.J., Penziner, A., Kanganis, D., Knowles, D., Traganos, F., and Silber, R. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II [published erratum appears in Cancer Res. 48:4716, 1988. Cancer Res.48:3537-3543, 1988.

    Google Scholar 

  163. Holden, J.A., Rolfson, D.H., and Wittwer, C.T. Human DNA topoisomerase II: evaluation of enzyme activity in normal and neoplastic tissues, Biochemistry 29:2127–2134, 1990.

    Article  PubMed  CAS  Google Scholar 

  164. Liu, L.F. DNA topoisomerase poisons as antitumor drugs. Ann Rev. Biochem. 58: 351–375, 1989.

    Article  PubMed  CAS  Google Scholar 

  165. Trash, C, Voelkel, K., DiNardo, S., and Sternglanz, R. Identification of Saccharomyces cerevisiae mutants deficient in DNA topoisomerase I activity. J. Biol. Chem. 259: 1375–1377, 1984.

    Google Scholar 

  166. Giovanella, B.C., Stehlin, J.S., Wall, M.E., Wani, M.C., Nicholas, A.W., Liu, L.F., Siber, R., and Potmesil, M. DNA topoisomerase I—targeted chemotherapy of human colon cancer in xenografts. Science 246:1046–1048, 1989.

    Article  PubMed  CAS  Google Scholar 

  167. Wall, M.E., Wani, M.C., and Cook, C.E. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 83:3888–3890, 1966.

    Article  Google Scholar 

  168. Gallo, R.C., Whang, P.J., and Adamson, R.H. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J. Natl Cancer Inst. 46:789–795, 1971.

    PubMed  CAS  Google Scholar 

  169. Gottlieb, J.A., Guarino, A.M., and Call, J.B. Preliminary pharmacological and clinical evaluation of caraptothecin sodium (NSC-100880).Cancer Chemotherap. Rep. 54: 461-470, 1970.

    Google Scholar 

  170. Gottlieb, J.A. and Luce, J.K. Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother. Rep. 56:103–105, 1972.

    PubMed  CAS  Google Scholar 

  171. Muggia, F.M., Creaven, P.J., Hansen, H.H., Cohen, M.H., and Selawry, O.S. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemotherap. Rep. 56:515–521, 1972.

    CAS  Google Scholar 

  172. Moertel, CG., Schutt, A.J., Reitemeier, R.J., and Hahn, R.G. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep. 56:95–101, 1972.

    PubMed  CAS  Google Scholar 

  173. Bosmann, H.B. Camptothecin inhibits macromolecular synthesis in mammalian cells but not in isolated mitochondria or E.coli. Biochem. Biophys. Res. Comm. 41:1412–1420, 1970.

    Article  CAS  Google Scholar 

  174. Kessel, D., Bosmann, H.B., and Lohr, K. Camptothecin effects on DNA synthesis in murine leukemia cells. Biochim. Biophys. Acta 269:210–216, 1972.

    Article  PubMed  CAS  Google Scholar 

  175. Drewinko, B., Freireich, E.J., and Gottlieb, J.A. Lethal activity of camptothecin sodium on human lymphoma cells. Cancer Res. 34:747–750, 1974.

    PubMed  CAS  Google Scholar 

  176. Li, L.H., Fraser, T.J., Olin, E.J., and Bhuyan, B.K., Action of camptothecin on mammalian cells in culture. Cancer Res. 32:2643–2650, 1972.

    PubMed  CAS  Google Scholar 

  177. Horwitz, S.B., Chang, C.K., and Grollman, A.P. Studies on camptothecin: I. Effects on nucleic acid and protein synthesis. Molec. Pharmacol. 7:632–644, 1971.

    CAS  Google Scholar 

  178. Horwitz, M.S. and Horwitz, S.B. Intracellular degradation of HeLa and adenovirus type 2 DNA induced by camptothecin. Biochem. Biophys. Res. Comm. 45:723–727, 1971.

    CAS  Google Scholar 

  179. Hsiang, Y.H., Hertzberg, R., Hecht, S., and Liu, L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260: 14873–14878, 1985.

    PubMed  CAS  Google Scholar 

  180. Mattem, M.R., Mong, S.M., Bartus, H.F., and Mirabelli, C.K. Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. Cancer Res. 47:1793–1798, 1987.

    Google Scholar 

  181. Covey, J.M., Jaxel, C., Kohn, K.W., and Pommier, Y. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res. 49:5016–5022, 1989.

    PubMed  CAS  Google Scholar 

  182. Hsiang, Y.H. and Liu, L.F. Identification of mammalian topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer. Res. 48:1722–1726, 1988.

    PubMed  CAS  Google Scholar 

  183. Hsiang, Y.H., Liu, L.F., Wall, M.E., Wani, M.C., Nicholas, A.W., Manikumar, G., Kirschenbaum, S., Silber, R., and Potmesil, M. DNA topoisomerase 1-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res. 49:4385–4389, 1989.

    PubMed  CAS  Google Scholar 

  184. Jaxel, C, Kohn, K.W., Wani, M.C., Wall, M.E., and Pommier, Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res. 49:1465–1469, 1989.

    PubMed  CAS  Google Scholar 

  185. Porter, S.E. and Champoux, J.J. The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I. Nucleic Acids Res. 17:8521–8532, 1989.

    Article  PubMed  CAS  Google Scholar 

  186. Kunimoto, T., Nitta, K., Tanaka, T., Uehara, N., Baba, H., Takeuchi, M., Yokokura, T., Sawada, S., Miyasaka, T., and Mutai, M. Antitumor activity of a 7-ethyl-10-[4-(l-piperidinoj-l-piperidinojcarbonyloxycamptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res. 47:5944–5947, 1987.

    PubMed  CAS  Google Scholar 

  187. Matsuzaki, T., Yokokura, T., Mutai, M., and Tsuruo, T. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother. Pharmacol. 21:308–312, 1988.

    Article  PubMed  CAS  Google Scholar 

  188. Tsuruo, T., Matsuzaki, T., Matsushita, M., Saito, H., and Yokokura, T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol. 21:71–74, 1988.

    CAS  Google Scholar 

  189. Johnson, R.K., McCabe, F.L., Faucette, L.F., Hertzberg, R.P., Kingsbury, W.D., Boehm, J.C., Caranfa, M.J., and Holden, K.G. SK&F 104864, a water soluble analog of camptothecin with broad spectrum activity in preclinical tumor models. Proc. Am. Assoc. Cancer. Res. 30:623, 1989.

    Google Scholar 

  190. Nitiss, J. and Wang, J.C. DNA topoisomerase-targeting antitumor drugs can be studies in yeast. Proc. Natl. Acad. Sci. USA 85:7501–7505, 1988.

    Article  PubMed  CAS  Google Scholar 

  191. Eng, W.K., Faucette, L., Johnson, R.K., and Sternglanz, R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol. Pharmacol. 34:755–760, 1988.

    PubMed  CAS  Google Scholar 

  192. Bjornsti, M.A., Benedetti, P., Viglianti, G.A., and Wang, J.C. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res. 49:6318–6323, 1989.

    PubMed  CAS  Google Scholar 

  193. Hsiang, Y.H., Lihou, M.G., and Liu, L.F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49:5077–5082, 1989.

    PubMed  CAS  Google Scholar 

  194. Avemann, K., Knippers, R., Koller, T., and Sogo, J.M. Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks. Mol. Cell Biol. 8:3026–3034, 1988.

    PubMed  CAS  Google Scholar 

  195. Andoh, T., Ishi, K., Suzuki, Y., Ikegami, Y., Kusunoki, Y., Takemoto, Y., and Okada, K. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc. Natl. Acad. Sci. USA 84:5565–5569, 1987.

    Article  PubMed  CAS  Google Scholar 

  196. Kjeldsen, E., Bonven, B., Andoh, T., Ishii, K., Okada, K., Bolund, L., and Westergaard, O. Characterization of a camptothecin-resistant human DNA topoisomerase I. J. Biol. Chem. 263:3912–3916, 1988.

    PubMed  CAS  Google Scholar 

  197. Gupta, R.S., Gupta, R., Eng, B., Lock, R.B., Ross, W.E., Hertzberg, R.P., Caranfa, M.J., and Johnson, R.K. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res. 48:6404–6410, 1988.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Daniel M. Sullivan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Warren E. Ross
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Fox Chase Cancer Center, USA

    Robert F. Ozols

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer Science+Business Media New York

About this chapter

Cite this chapter

Sullivan, D.M., Ross, W.E. (1991). Resistance to inhibitors of DNA topoisomerases. In: Ozols, R.F. (eds) Molecular and Clinical Advances in Anticancer Drug Resistance. Cancer Treatment and Research, vol 57. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3872-1_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3872-1_4

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6726-0

  • Online ISBN: 978-1-4615-3872-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation